ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations. © 2014 The Author(s).
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe / A. Mocroft, P. Reiss, A. Rakhmanova, D. Banhegyi, A.N. Phillips, S. De Wit, M. Ristola, J.D. Lundgren, J. Grarup, O. Kirk, M. Kundro, N. Vetter, R. Zangerle, I. Karpov, A. Vassilenko, O. Suetnov, N. Clumeck, M. Delforge, R. Colebunders, L. Vandekerckhove, V. Hadziosmanovic, K. Kostov, J. Begovac, L. Machala, D. Jilich, D. Sedlacek, J. Nielsen, G. Kronborg, T. Benfield, M. Larsen, J. Gerstoft, T. Katzenstein, A.-.E. Hansen, P. Skinhoj, C. Pedersen, L. Ostergaard, K. Zilmer, J. Smidt, C. Katlama, J.-. Viard, P.-. Girard, J.M. Livrozet, P. Vanhems, C. Pradier, F. Dabis, D. Neau, J. Rockstroh, R. Schmidt, J. van Lunzen, O. Degen, H.J. Stellbrink, M.M. Bickel, J. Bogner, G. Fatkenheuer, J. Kosmidis, P. Gargalianos, G. Xylomenos, J. Perdios, G. Panos, A. Filandras, E. Karabatsaki, H. Sambatakou, F. Mulcahy, I. Yust, D. Turner, M. Burke, S. Pollack, G. Hassoun, S. Maayan, S. Vella, R. Esposito, I. Mazeu, C. Mussini, C. Arici, R. Pristera, F. Mazzotta, A. Gabbuti, V. Vullo, M. Lichtner, A. Chirianni, E. Montesarchio, M. Gargiulo, G. Antonucci, A. Testa, G. D'Offizi, C. Vlassi, M. Zaccarelli, A. Antorini, A. Lazzarin, A. Castagna, N. Gianotti, M. Galli, A. Ridolfo, B. Rozentale, I. Zeltina, S. Chaplinskas, T. Staub, R. Hemmer, V. Ormaasen, A. Maeland, J. Bruun, B. Knysz, J. Gasiorowski, A. Horban, E. Bakowska, A. Grzeszczuk, R. Flisiak, A. Boron-Kaczmarska, M. Pynka, M. Parczewski, M. Beniowski, E. Mularska, H. Trocha, E. Jablonowska, E. Malolepsza, K. Wojcik, F. Antunes, M. Doroana, L. Caldeira, K. Mansinho, F. Maltez, D. Duiculescu, N. Zakharova, S. Buzunova, D. Jevtovic, M. Mokras, D. Stanekova, J. Tomazic, J. Gonzalez-Lahoz, V. Soriano, P. Labarga, J. Medrano, S. Moreno, J.M. Rodriguez, B. Clotet, A. Jou, R. Paredes, C. Tural, J. Puig, I. Bravo, J.M. Gatell, J.M. Miro, P. Domingo, M. Gutierrez, G. Mateo, M.A. Sambeat, A. Blaxhult, L. Flamholc, A. Thalme, A. Sonnerborg, B. Ledergerber, R. Weber, P. Francioli, M. Cavassini, B. Hirschel, E. Boffi, H. Furrer, M. Battegay, L. Elzi, E. Kravchenko, N. Chentsova, V. Frolov, G. Kutsyna, S. Servitskiy, M. Krasnov, A.M. Johnson, D. Mercey, A. Phillips, M.A. Johnson, M. Murphy, J. Weber, G. Scullard, M. Fisher, C. Leen, J. Gatell, B. Gazzard, A. D'Arminio Monforte, A. Cozzi-Lepri, D. Grint, A. Schultze, L. Shepherd, M. Sabin, D. Podlekareva, J. Kjaer, L. Peters, J. Tverland, A.H. Fischer, R. Thiebaut, D. Burger, M. Losso. - In: INFECTION. - ISSN 0300-8126. - 42:4(2014 Aug 01), pp. 757-762. [10.1007/s15010-014-0630-4]
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
M. Galli;A. D'ARMINIO MONFORTE;
2014
Abstract
ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations. © 2014 The Author(s).File | Dimensione | Formato | |
---|---|---|---|
15010_2014_Article_630.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
292.2 kB
Formato
Adobe PDF
|
292.2 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.